Medtronic Reports Strong Q4 & FY26 Results, Highest Annual Revenue Growth in Decade, Raises Dividend & Issues Positive FY27 Guidance

summarizeSummary

Medtronic reported strong Q4 and full-year fiscal 2026 results, including its highest annual organic revenue growth in a decade, an EPS beat for the quarter, and a 49th consecutive dividend increase, alongside positive FY27 guidance.

check_boxKey Events

• Strong Q4 and FY26 Financial Performance

  Medtronic reported Q4 revenue of $9.8 billion, an increase of 6.6% organically (90 basis points ahead of implied guidance), and achieved 5.8% organic revenue growth for fiscal year 2026, marking its highest annual growth in 10 years.

• EPS Beat and Met Guidance

  Q4 non-GAAP diluted EPS of $1.55 was ahead of guidance, and full-year non-GAAP diluted EPS of $5.53 was within the previously revised guidance range of $5.50-$5.54.

• Increased Dividend for 49th Consecutive Year

  The company announced its 49th consecutive annual dividend increase, raising the quarterly dividend for Q1 FY27 to $0.72 per ordinary share, implying an annual amount of $2.88 per share.

• Positive FY27 Outlook

  Medtronic provided strong guidance for fiscal year 2027, projecting organic revenue growth of 6.75% to 7.25% and non-GAAP diluted EPS in the range of $5.90 to $6.00.

auto_awesomeAnalysis

This 8-K reports strong financial results for Medtronic, with Q4 revenue and EPS exceeding expectations and full-year organic revenue growth reaching a 10-year high. The company also provided robust guidance for fiscal year 2027 and announced its 49th consecutive annual dividend increase, signaling confidence in its future performance and commitment to shareholder returns. These positive operational and financial updates are particularly notable as the stock is currently trading near its 52-week low, potentially providing a catalyst for investor sentiment.